Tuesday, 14 May 2019 – 7:00pm
This presentation will deal with hormone therapy as used in treating various types of advanced prostate cancer:
- hormone sensitive non-metastatic
- hormone sensitive metastatic
- castrate resistant non-metastatic
Dr. Loblaw is one of our favourite speakers and is the referring physician for our Cruisin’ for a Cure show on September 8th.
Dr. Loblaw is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto.
Dr. Loblaw received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University. He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from Royal College’s Clinician Investigator Program all at the University of Toronto.
Dr. Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particular interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy.
Dr. Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Scientist at the Sunnybrook Research Institute. A Fellow of the American Society of Clinical Oncology (FASCO), he was previous Co-Chair of the ASCO’s Genitourinary Advisory Group and remains Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored over 200 peer-reviewed papers and has been awarded grant funding of over $35M.
You can forward your questions or suggestions to: info@pccnbrampton.ca or telephone 905-458-6650.
We look forward to seeing you downstairs at Wellspring Chinguacousy Cancer Support Centre, 5 Inspiration Way, Brampton, ON L6R 0L7, west of Torbram Road and south of Father Tobin Drive. Parking is well lit and free and there is an elevator if you require one.